文献速递胸部肿瘤

肿瘤内埃希菌属与晚期非小细胞肺癌患者单药免疫检查点抑制剂治疗生存改善相关

Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2024-07-22

本研究通过分析958例接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者的肿瘤内微生物组,发现肿瘤内埃希菌属读数映射与单药免疫检查点抑制剂治疗患者的总生存期显著延长相关(16个月 vs 11个月;HR 0.73,95%CI 0.59-0.92;P=0.0065),但在化疗免疫联合治疗患者中无此关联。该关联在调整PD-L1表达等预后因素的多变量分析中仍具统计学显著性(P=0.023),并在772例外部独立队列中得到验证。

要点

  • 肿瘤内埃希菌属检测与单药免疫检查点抑制剂治疗患者总生存期延长相关(16个月 vs 11个月)。
  • 该关联在调整PD-L1表达等预后因素后仍显著(P=0.023),并在外部验证队列中确认。
  • 在化疗免疫联合治疗患者中未观察到肿瘤内埃希菌属与总生存期的关联。

核心结论

  • 在两个独立的非小细胞肺癌患者队列中,肿瘤内潜在埃希菌属读数映射与单药免疫检查点抑制剂治疗生存相关。

研究设计与样本

  • 研究纳入958例接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者,通过将未映射的下一代测序读数与细菌基因组数据库比对来检测肿瘤内微生物组。
  • 使用无模板对照(n=2378)过滤潜在环境污染物。
  • 采用单变量和多变量分析评估肿瘤内埃希菌属检测对总生存期的影响,并在772例外部独立队列中验证。
  • 进行了埃希菌属荧光原位杂交(FISH)和转录组分析。

主要发现

  • 在发现队列中,肿瘤内埃希菌属读数映射与接受单药免疫检查点抑制剂治疗患者的总生存期显著延长相关(16个月 vs 11个月;风险比0.73[95%CI 0.59-0.92];P=0.0065),但在化疗免疫联合治疗患者中无此关联。
  • 在单药免疫检查点抑制剂队列中,调整PD-L1表达等预后特征的多变量分析后,与总生存期的关联仍具统计学显著性(P=0.023)。
  • 外部验证队列的单变量和多变量分析证实了在单药免疫检查点抑制剂治疗患者中与总生存期改善的关联,而在化疗免疫联合治疗患者中未观察到。
  • FISH染色与连续苏木精-伊红切片的共配准支持埃希菌属位于肿瘤细胞内。
  • 转录组分析显示埃希菌属阳性样本与免疫细胞浸润的表达特征相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSEThe impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non-small-cell lung cancer (NSCLC) is unknown. Preclinically, intratumoral Escherichia is associated with a proinflammatory tumor microenvironment and decreased metastases. We sought to determine whether intratumoral Escherichia is associated with outcome to ICI in patients with NSCLC.PATIENTS AND METHODSWe examined the intratumoral microbiome in 958 patients with advanced NSCLC treated with ICI by querying unmapped next-generation sequencing reads against a bacterial genome database. Putative environmental contaminants were filtered using no-template controls (n = 2,378). The impact of intratumoral Escherichia detection on overall survival (OS) was assessed using univariable and multivariable analyses. The findings were further validated in an external independent cohort of 772 patients. Escherichia fluorescence in situ hybridization (FISH) and transcriptomic profiling were performed.RESULTSIn the discovery cohort, read mapping to intratumoral Escherichia was associated with significantly longer OS (16 v 11 months; hazard ratio, 0.73 [95% CI, 0.59 to 0.92]; P = .0065) in patients treated with single-agent ICI, but not combination chemoimmunotherapy. The association with OS in the single-agent ICI cohort remained statistically significant in multivariable analysis adjusting for prognostic features including PD-L1 expression (P = .023). Analysis of an external validation cohort confirmed the association with improved OS in univariable and multivariable analyses of patients treated with single-agent ICI, and not in patients treated with chemoimmunotherapy. Escherichia localization within tumor cells was supported by coregistration of FISH staining and serial hematoxylin and eosin sections. Transcriptomic analysis correlated Escherichia-positive samples with expression signatures of immune cell infiltration.CONCLUSIONRead mapping to potential intratumoral Escherichia was associated with survival to single-agent ICI in two independent cohorts of patients with NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Elkrief A, Montesion M, Sivakumar S, et al. Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024. PMID: 39038258. doi:10.1200/JCO.23.01488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。